# Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss

> **NCT03174951** · PHASE2 · COMPLETED · sponsor: **Tabriz University of Medical Sciences** · enrollment: 50 (actual)

## Conditions studied

- Recurrent Pregnancy Loss

## Interventions

- **DRUG:** IVIg

## Key facts

- **NCT ID:** NCT03174951
- **Lead sponsor:** Tabriz University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-20
- **Primary completion:** 2017-03-10
- **Final completion:** 2017-06-20
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174951, "Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03174951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*